5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial-Reference-Cited by-同舟云学术

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

Published:2016-06 Issue:6 Volume:17 Page:791-800
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gianni Luca,Pienkowski Tadeusz,Im Young-Hyuck,Tseng Ling-Ming,Liu Mei-Ching,Lluch Ana,Starosławska Elżbieta,de la Haba-Rodriguez Juan,Im Seock-Ah,Pedrini Jose Luiz,Poirier Brigitte,Morandi Paolo,Semiglazov Vladimir,Srimuninnimit Vichien,Bianchi Giulia Valeria,Magazzù Domenico,McNally Virginia,Douthwaite Hannah,Ross Graham,Valagussa Pinuccia

Publisher

Elsevier BV

Subject

Oncology

Reference20 articles.

1. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy;Baselga;J Clin Oncol,2010

2. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial;Gianni;Lancet Oncol,2012

3. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA);Schneeweiss;Ann Oncol,2013

4. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer;Baselga;N Engl J Med,2012

5. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015

Cited by 671 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

2. Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update;Journal of Clinical Oncology;2024-09-11

3. Systematic review of added immunotherapy in traditional treatment for HER2 positive breast cancer patients;Innovative Practice in Breast Health;2024-09

4. Peri-Tumoural Lipid Composition and Hypoxia for Early Immune Response to Neoadjuvant Chemotherapy in Breast Cancer;International Journal of Molecular Sciences;2024-08-28

5. Pathological response and safety of albumin-bound paclitaxel as a neoadjuvant treatment for HER2-positive breast cancer compared to docetaxel combined with anti-HER2 therapy: a real-world study;Frontiers in Oncology;2024-08-21